Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin reported a series of option exercises and share sales on July 15, 2026. She exercised stock options for 4,302 shares of common stock at exercise prices of $7.1400 and $9.0800 per share, then sold 4,302 common shares in four transactions at weighted average prices of $147.1365, $148.4018, $149.2667 and $150.2529 per share. After the final sale she held 0 common shares directly, while the options involved were fully vested, and all trades were effected under a Rule 10b5-1 trading plan adopted on August 19, 2025 and approved under the company’s insider trading policy.
Palvella Therapeutics Inc. indicates that Kathleen Goin plans to sell 4,302 shares of common stock through Piper Sandler & Co. on 07/15/2026, with an aggregate market value of $643,923.36. Shares outstanding are listed as 14,342,844, and the shares trade on Nasdaq.
The shares to be sold were acquired via a stock option exercise for cash. Goin also sold 4,302 shares on each of 04/15/2026, 05/20/2026, and 06/17/2026, for aggregate prices of $547,398.96, $475,630.84, and $476,372.94, respectively.
Palvella Therapeutics is advancing its QTORIN platform for rare dermatologic and vascular malformation diseases. Lead candidate QTORIN 3.9% rapamycin anhydrous gel achieved highly statistically significant Phase 3 SELVA results in microcystic lymphatic malformations, supporting a rolling New Drug Application (NDA) submission planned for completion in 2H 2026 and potential U.S. approval and launch in 1H 2027. The program holds Breakthrough, Fast Track and Orphan designations and targets an estimated >30k diagnosed U.S. patients, with internal research indicating potential U.S. peak sales of >$1 billion at orphan-level pricing.
The same formulation is being developed for cutaneous venous malformations, where positive Phase 2 TOIVA data and Fast Track status underpin a planned Phase 3 initiation in Q4 2026, and for clinically significant angiokeratomas (Phase 2 initiated in April 2026). A second key program, QTORIN pitavastatin, is being advanced for DSAP with Phase 2 initiation expected in 2H 2026. Palvella reports an oversubscribed $230mm financing in Q1 2026 and $262 million in cash as of March 31, 2026, with 2026 cash expenses estimated at [~$90-95mm], which it states provides potential funding through multiple regulatory filings, an initial launch and several Phase 2 readouts.
Palvella Therapeutics director Matthew Pauls received a grant of stock options representing rights to buy 6,000 shares of common stock. The options have an exercise price of 154.84 per share and expire on June 29, 2036. They vest in 36 equal monthly installments, conditioned on his continued service, and his derivative holdings after this grant total 6,000 options.
PALVELLA THERAPEUTICS, INC. director Matthew Pauls has filed an initial Form 3, which is the first statement of his beneficial ownership as an insider. This filing reports no purchases, sales, gifts, or other share movements and lists no derivative positions for him in this report.
Palvella Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed Matthew Pauls as a Class I director, with his initial term running until the company’s 2027 annual meeting of stockholders.
Pauls, 56, is currently Chief Executive Officer of Savara, Inc. and holds multiple other biopharmaceutical board roles, bringing extensive rare disease and commercialization experience. As a non-employee director, he will receive customary cash retainers under Palvella’s director compensation policy and was granted an option to purchase 6,000 shares of common stock, vesting in equal monthly installments over 36 months, subject to continued service. The Board determined he is independent under Nasdaq listing rules, and there are no related party transactions or family relationships requiring disclosure.
Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options for 4,302 shares of common stock at strike prices of $7.14 and $9.08 per share, then sold 4,302 shares in open-market transactions on June 17, 2026 at weighted average prices around $110–$112 per share. The filing shows these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2025. Following the sales, she holds 0 shares of Palvella common stock directly, and no remaining option positions are listed in this filing.
Palvella Therapeutics submitted a Form 144 notice indicating proposed sale activity in its Common Stock via a stock option exercise on 06/17/2026. The filing lists a transaction value of $476,372.94 and references Nasdaq as the market.
The excerpt also shows three prior reported sales by Kathleen Goin during the past three months with values of $507,611.05, $547,398.96 and $475,630.84. The filing identifies the broker address for Piper Sandler & Co.
Palvella Therapeutics CFO Matthew E. Korenberg exercised stock options to acquire 1,000 shares of common stock at $13.60 per share. Following the transaction, he directly owns 1,000 common shares and retains stock options covering 166,100 shares.
The exercised options have an exercise price of $13.60 and an expiration date of December 13, 2034. According to the vesting terms, 25% of the options vest on October 16, 2025, with the remaining 75% vesting in equal monthly tranches over the next 36 months.
Palvella Therapeutics, Inc. stockholders approved an amendment to the company’s 2024 Equity Incentive Plan, increasing the authorized shares issuable under the plan by 750,000 shares. This amendment had been previously approved by the Board of Directors, subject to stockholder approval, and became effective immediately at the 2026 Annual Meeting.
As of April 13, 2026, there were 14,323,686 outstanding common shares entitled to vote. Stockholders elected three Class III directors—George M. Jenkins, Todd C. Davis and John Doux, M.D.—to serve until the 2029 Annual Meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers and chose to hold future advisory votes on executive compensation every year. They approved both the equity plan amendment and a potential adjournment proposal, although adjournment was ultimately unnecessary.